Skip to main content
NewslettersWatchlist

Avicanna Inc(AVCN-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.2400
Day High0.2650
Open:0.2550
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
GlobeNewswire
Avicanna Reports Q3 2024
GlobeNewswire
Avicanna Announces Closing of Non-Brokered Private Placement
GlobeNewswire
Avicanna Announces Medical Cannabis Real World Evidence Study through MyMedi.ca  
Baystreet
Stocks in play: Avicanna Inc.
GlobeNewswire
Avicanna Announces Repayment of Debentures
GlobeNewswire
Avicanna Announces Closing of Non-Brokered Private Placement
GlobeNewswire
Avicanna Announces United States Patent and Trademark Office Issuance of Patent on Topical Technology
GlobeNewswire
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Denmark
GlobeNewswire
Avicanna Reports Q2 2024
GlobeNewswire
Avicanna Announces Changes of Auditors
AI-generated - The Globe and Mail
Avicanna: Top 10 Undervalued Healthcare Sector Stocks on TSX (AVCN)
GlobeNewswire
Avicanna Subsidiary Completes Export of Aureus Branded CBG into Singapore
GlobeNewswire
Avicanna Announces Results of Annual General Meeting & Provides Corporate Update
GlobeNewswire
Avicanna General Meeting
Baystreet
Stocks in play: Avicanna Inc.
GlobeNewswire
Avicanna Announces USPTO Issuance of Patent SEDDS Technology
GlobeNewswire
Avicanna to Present at the Life Science Investor Forum June 20th, 2024
AI-generated - The Globe and Mail
Avicanna: Top 10 Undervalued Growth Stocks on TSX (AVCN)
AI-generated - The Globe and Mail
Avicanna: Top 10 Undervalued Healthcare Sector Stocks on TSX (AVCN)
AI-generated - The Globe and Mail
Avicanna: Top 10 Undervalued Drug Manufacturers Industry Stocks (AVCN)
GlobeNewswire
Avicanna Reports Q1 2024 and First Positive Adjusted EBIDTA Quarter
GlobeNewswire
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

Profile

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.